Last reviewed · How we verify

NCT04322734

Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders

Recruiting now Last updated 27 December 2024
What this trial tests

trial in Autism Spectrum Disorder in 500 participants. Currently enrolling.

Timeline
13 December 2023
Primary endpoint
31 December 2028
31 December 2028

Quick facts

Lead sponsorSouthwest Autism Research & Resource Center
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment500
Start date13 December 2023
Primary completion31 December 2028
Estimated completion31 December 2028
Sites2 locations across United States

Conditions studied

Sponsor

Southwest Autism Research & Resource Center — full company profile →

Who can join

Under 18, any sex, with Autism Spectrum Disorder or Mitochondrial Pathology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study involves up to 5 visits for a fasting blood draw, behavioral assessments, and/or questionnaires. Other samples may be collected when appropriate. This study is currently recruiting. There is no cost for visits or study-related exams.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Blood RNA Sequencing Indicates Upregulated <i>BATF2</i> and <i>LY6E</i> and Downregulated <i>ISG15</i> and <i>MT2A</i> Expression in Children with Autism Spectrum Disorder.
    Voinsky I, Zoabi Y, Shomron N, Harel M, et al · · 2022 · cited 3× · PMID 36077244 · DOI 10.3390/ijms23179843

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other Southwest Autism Research & Resource Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04322734.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing